期刊文献+

背景滴定用于阿片类药物耐受癌痛患者的可行性分析 被引量:3

Feasibility of background morphine titration for management of cancer pain in opioid tolerant patients
下载PDF
导出
摘要 目的探讨背景滴定用于阿片类药物耐受癌痛患者镇痛治疗的可行性。方法 38例阿片类药物耐受的癌痛控制不稳定患者,分为背景滴定组和短效吗啡滴定组分别进行滴定,比较两组患者滴定周期、最高疼痛评分、滴定达稳态时间、滴定达稳态阿片类药物剂量及不良反应。结果背景滴定组与短效吗啡滴定组的滴定周期分别为(1.4±0.5)、(2.1±0.8)次,滴定达稳态时间分别为(19.9±10.2)、(24.5±8.4)h,滴定过程中最高疼痛评分分别为(5.4±0.8)、(6.3±0.9)分,两组间比较均有统计学差异(均P<0.05);两组不良反应发生率则无统计学差异(P>0.05)。结论背景滴定用于阿片类药物耐受癌痛患者的镇痛治疗,疼痛控制迅速平稳,不良反应可耐受,是一种安全有效的镇痛治疗方案。 Objective To examine the efficacy and safety of background intravenous morphine titration for the manage-ment of cancer pain in opioid tolerant patients. Methods Thirty eight opioid tolerant patients with uncontrol ed cancer pain were divided into two groups:background titration group and short- action morphine titration group. The titration cycles, the highest numerical rating scale (NRS), the time to steadily pain control, the dosage of opioid analgesics and adverse effect were com-pared between two groups. Results The titration cycle, the highest numerical rating scale and the time to steadily pain control in background titration group and short- acting morphine titration group were(1.4 ±0.5)vs(2.1 ±0.8),(5.4 ±0.8)vs(6.3 ±0.9) and(19.9±10.2)h vs(24.5±8.4)h, respectively(al P〈0.05).There were no statistical differences in the occurrence of adverse effect between two groups (P〉0.05). Conclusion Background titration is rapid, steady and safe for the management of cancer pain in opioid tolerant patients.
出处 《浙江医学》 CAS 2014年第13期1144-1146,1181,共4页 Zhejiang Medical Journal
关键词 癌痛 滴定 阿片类药物耐受 Cancer pain Titration Opioid tolerance
  • 相关文献

参考文献5

二级参考文献70

  • 1张冠中,谢晓冬,刘大为.盐酸羟考酮控释片治疗晚期癌症疼痛的临床应用[J].中国肿瘤临床,2007,34(2):72-74. 被引量:25
  • 2Kapil R,Nolting A,Roy P,et al.Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen:two randomized,open-label,crossover studies in healthy adult volunteers.Clin Ther,2004,26(12):2015-2025.
  • 3Schrijvers D.Pain control in cancer:recent findings and trends.Ann Oncol,2007,18 Suppl 9:ix37-42.
  • 4Salzman RT,Roberts MS,Wild J,et al.Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control.J Pain Symptom Manage,1999,18(4):271-279.
  • 5Trescot AM,Glaser SE,Hansen H,et al.Effectiveness of opioids in the treatment of chronic non-cancer pain.Pain Physician,2008,11(2 Suppl):S181-200.
  • 6Suzuki T,Morishita M,Ito E,et al.Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer.Am J Ther,2008,15(1):31-35.
  • 7Czarnecki ML,Jandrisevits MD,Theiler SC,et al.Controlled-release oxycodone for the management of pediatric postoperative pain.J Pain Symptom Manage,2004,27(4):379-386.
  • 8De Luca A,Coupar IM.Insights into opioid action in the intestinal tract.Pharmacol Ther,1996,69(2):103-115.
  • 9Pappagallo M.Incidence,prevalence,and management of opioid bowel dysfunction.Am J Surg,2001,182(5A Suppl):11S-18S.
  • 10Herndon CM,2nd JKC,Hallin PA.Management of opioid-induced gastrointestinal effects in patients receiving palliative care.Pharmacotherapy,2002,22(2):240-250.

共引文献359

同被引文献35

引证文献3

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部